"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 8 | 10 |
| 2009 | 2 | 8 | 10 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 9 | 9 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 7 | 7 |
| 2014 | 3 | 11 | 14 |
| 2015 | 5 | 10 | 15 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 10 | 12 |
| 2019 | 7 | 4 | 11 |
| 2020 | 4 | 6 | 10 |
| 2021 | 2 | 7 | 9 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 4 | 5 | 9 |
| 2025 | 4 | 2 | 6 |
| 2026 | 2 | 5 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Laser-programmable glycosaminoglycan-based nanocarriers co-deliver hypocrellin B and doxorubicin for spatiotemporal chemo-photothermal therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2026 Nov; 267:115919.
-
Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort. Leuk Res. 2026 Aug; 167:108265.
-
Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study. ESC Heart Fail. 2026 May 05; 13(3).
-
Malignant peripheral nerve sheath tumors: a report from Children's Oncology Group study ARST0332. J Natl Cancer Inst. 2026 May 01; 118(5):829-838.
-
Aging and DNA damage are associated with the development of endothelial cell clonal expansion. Am J Physiol Heart Circ Physiol. 2026 06 01; 330(6):H1876-H1882.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatr Blood Cancer. 2026 May; 73(5):e70228.
-
A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDox?. Drug Deliv Transl Res. 2026 Aug; 16(8):2911-2920.
-
MitoQ reduces senescence burden in doxorubicin-treated endothelial cells by reducing mitochondrial ROS and DNA damage. Am J Physiol Heart Circ Physiol. 2025 11 01; 329(5):H1154-H1161.
-
Targeted activation of Nrf2 at sites of oxidative stress reverses doxorubicin-induced cognitive impairments in mice. Brain Behav Immun. 2025 Oct; 129:547-556.